The regulatory physique for therapeutic items in Australia is reviewing complaints involving the noncompliant advertising of medical cannabis merchandise.
The Therapeutic Goods Administration (TGA) says it “has written to a number of entities in relation to noncompliance with the law with instruction to cease unlawful behaviour.”
“The majority of respondents have brought themselves into compliance. For those that have not, we are considering appropriate action,” the regulator stated in a press release on Tuesday.
Criminal offences and civil penalties could apply to breaches of the Narcotic Drugs Act and the Therapeutic Goods Act, the TGA stated.
The assessment is prioritizing complaints the place shoppers “may be at risk because the medicinal cannabis products offered for sale have not been through regulatory checks,” the TGA stated.
Rhys Cohen, principal advisor for FreshLeaf Analytics, wrote that the advertising of regulated medicines is strictly controlled in Australia,
“The TGA clarified how these regulations apply to the medical cannabis industry back in November 2019. In short, it is a breach of the regulations to advertise or promote the use of a specific prescription medicine or a class of prescription medicines to the general public,” in response to Rhys.
The investigation into illegal cannabis advertising comes because the TGA expands the variety of high quality inspections for imported medical cannabis.
Most Australian medical cannabis remains to be imported as native producers proceed to ramp up manufacturing.
In 2019, Australia imported some 3,700 liters (977 gallons) of medical cannabis oil merchandise in addition to 204 kilograms of flower from Canada for medical and scientific use.